Background. Diagnostic criteria for sarcopenia from appendicular lean mass (ALM), strength, and performance have been proposed, but little is known regarding the progression of sarcopenia. We examined the time course of sarcopenia and determinants of transitioning toward and away from sarcopenia.
P ROGRESSIVE loss of skeletal muscle is a hallmark of advancing age. Age-related loss of muscle has multiple contributing factors including bed rest, inactivity, chronic disease, pain, and some drugs (1) (2) (3) . Low muscle with muscle weakness increases the risk of falls, fractures, loss of function, and disability (4) . Therefore, identification of individuals with low muscle mass and/or strength is important in geriatric care.
The term sarcopenia has been defined as age-related muscle loss with low muscle strength and/or low muscle performance (5, 6) . To facilitate the identification of individuals with sarcopenia, several definitions and diagnostic criteria have been proposed (7) (8) (9) . These definitions recognize that sarcopenia is multidimensional and occurs across a continuum, varying in severity and stage: (a) presarcopenia: low muscle mass; (b) sarcopenia: low muscle mass with low muscle strength or low performance; and (c) severe sarcopenia: low muscle mass, low muscle strength, and low performance (8) . Comparatively, little is known about the progression of sarcopenia and transitions in and out of sarcopenia. Therefore, the purpose of this study was to examine the time course of sarcopenia and to explore potential determinants of transition between stages of sarcopenia using serial measures of appendicular lean mass (ALM), grip strength, and gait speed over 9 years from the Health, Aging, and Body Composition Study.
Methods

Study Population
The Health, Aging, and Body Composition Study is a prospective population-based study of 3,075, black and white men and women initially aged 70-79 in the Memphis, Tennessee, and Pittsburgh, Pennsylvania areas. All participants reported no difficulty walking one-quarter mile or climbing 10 steps without resting. Additional study details have been published (4) . All participants signed informed consent forms approved by institutional review boards of the clinic sites.
Body Composition
The Supplementary Material provides details of computed tomography image analysis. Briefly, total body dual energy x-ray absorptiometry was performed (Hologic QDR4500A, Waltham, NY) annually from baseline (year 1) through year 10 with the exception of years 7 and 9 when there was no clinic visit. ALM the sum of bone-free lean tissue in the arms and legs was standardized for height (m 2 ). Low ALM was defined as the 20th percentile of ALM: less than 7.95 kg/m 2 for men and less than 6.24 kg/m 2 for women (10) .
Performance
Gait speed was measured annually from baseline through year 10 with the exception of years 7 and 9. Usual gait speed was determined from assessments 6 m (years 1, 4, 6, and 10), 20 m (years 3 and 5) or 2 minutes (years 2 and 8) (6) . Gait speed less than 1.0 m/s was used to identify low physical performance (7, 8) .
Muscle Strength
Grip strength was measured using an isometric dynamometer (Jaymar, Boling-brook, IL). Grip strength was assessed as the maximum force of two trials with each hand at baseline, years 2, 4, 6, 8, and 10 and in subsets of participants at years 3 and 5. Low muscle strength was defined as grip strength less than 30 kg for men and less than 20 kg for women, which are values that discriminate early stages of reduced physical function in older adults (5) .
Sarcopenia-Related Variables
Previously identified risk factors for sarcopenia (11) (12) (13) (14) (15) were examined to assess factors related to transitions toward and away from sarcopenia. Variables were all assessed at year 1. Body mass index (BMI) was assessed as a continuous variable as categories for underweight, normal weight, overweight, and obesity in old age are controversial (16) . Physical activity was assessed as kcal/wk spent walking or exercising in the prior week (17) . Self-reported health was categorized as excellent, very good to good, and fair to poor. Pain and knee pain was self-reported in the previous 30 days. Knee pain was missing in one participant. Smoking was categorized as never, former, or current. Diabetes was determined from self-report and medications; impaired fasting glucose was defined as more than or equal to 6.1 mmol/L. Details of mediator analyses are provided in Supplementary Material. Serum was collected following an overnight fast. Insulin was not measured in participants with known diabetes (N = 305). Free testosterone, interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-α) were measured by ELISA kits. Participants with missing data were excluded only from analysis of transition predictors.
Mortality was determined from death certificates, hospital records, and interview with next of kin through August 10, 2011 representing 14 years of follow-up.
Statistical Analyses
ALM, muscle performance, and strength over 9 years were analyzed with discrete hidden Markov modeling (HMM) (18, 19) . HMM uses information from each participant's history to conceptualize the course of sarcopenia as a sequence of observable indicators of sarcopenia driven by an underlying sequence of latent states. The optimal model is determined from Bayesian goodness-of-fit criterion (20) (Figure 1 ). The HMM produces (a) states characterized by scoring the three sarcopenia criteria at each point in time, (b) estimates for the prevalence of each state at any given time point, and (c) estimates for transition probabilities between states. Death was included as a final absorbing state (N = 840 died during follow-up).
Determinants of transitioning away from normal ALM, strength, and performance (N = 2,355) toward sarcopenia were assessed with logistic regression. Since sarcopenia was the end point, the death state was excluded, but deceased individuals remained in the analysis. Logistic regression was also used to assess determinants of remaining presarcopenic or transitioning toward sarcopenia versus transitioning to more normal states in initially presarcopenic individuals (N = 536). Statistical analyses were performed with SAS 9.2 PROC GENMOD and specialized programs (18, 21) written in MATLAB (Mathworks Inc., Natick, MA).
Results
Individuals without follow-up data were excluded (N = 147) and were more likely to be black, current smokers, report low physical activity, have poor health, lower grip strength, and lower gait speed (p < .05 for all). Baseline characteristics of the 2,928 included participants are shown in Table 1 . On average, men and women were overweight and more than 50% had diabetes or impaired fasting glucose. Most participants reported low levels of activity, a history of pain, and very good or good health.
HMM resulted in eight state profiles of ALM, strength, and performance ( Figure 2 ). Within a state, longer bars represent a higher probability of having normal values.
States are approximately ordered in descending order. State 1 represents the most normal state: nearly all participants have ALM above the 20th percentile, grip strength more than 20 kg (women) or more than 30 kg (men), and gait speed more than 1 m/s. States 2 and 3 represent intermediate subclinical states, and state 4 is characterized by low function (low strength and performance). State 5 approximates presarcopenia, states 6 and 7 approximate sarcopenia, and state 8 is death. Participants in this population were selected to be initially well functioning. As a result, participants meeting criteria for severe sarcopenia averaged to 1.5% across all time points and was too low to constitute a state.
The prevalence of states at each time over the 9-year period is shown in Figure 3 . The most normal state is at the bottom, and death is at the top. Over time, the prevalence of the normal state declines from 54% to less than 30%. The prevalence of the presarcopenia state declines from 21% to less than 10%. Conversely, the prevalence of sarcopenia states increases, as does the prevalence of the low function state and death.
Initial state and transition probabilities are shown in Table 2 . Overall, individuals tended to remain in their current state. In the normal state, 88% of individuals remained there, 1% transitioned to presarcopenia, and 3% died. In intermediate state 2, 88% remained in that state, 3% transitioned to sarcopenia, and 6% died. In intermediate state 3, 83% of individuals remained in that state, 3% transitioned to sarcopenia, and 4% died. In the low-functioning state, 86% remained there, 2% transitioned to more normal states, and 13% died. For individuals with presarcopenia, 7% transitioned to sarcopenia, 4% transitioned to more normal states, and 4% died. Only 1% (state 6) to 2% (state 7) of sarcopenic individuals transitioned to more normal states, 12% (state 6) and 8% (state 7) died. Notes: IU = international units; SD = standard deviation. Numbers may not sum to total N due to missing data as outlined in the Methods. Model of eight states of appendicular lean mass (ALM), muscle performance and strength. Bars represent the probability of observing a participant having gait speed, ALM or grip strength above their respective cut-points thus longer bars indicate higher probability of having a normal measure (ie, in state 1, the most normal state nearly all participants have gait speed >1 m/s, and all participants have ALM and grip strength above cut-points). States 2 and 3 are intermediate states, state 4 is a state characterized by low function, state 5 represents presarcopenia, states 6 and 7 represent sarcopenia, and state 8 is death. Participants can be classified as belonging to any of these eight states and may transition to any of these states during the 9-year follow-up period. ALM = appendicular lean mass. 
Discussion
To our knowledge, this is the first study to examine the natural time course of transitions between sarcopenia stages. Our results show that few participants who entered old age in the normal state of ALM, strength, and performance developed presarcopenia, and none became sarcopenic despite an age range of 79-88 at the end of the study. Individuals who transitioned to sarcopenia did so via declines in strength and performance, emphasizing the multidimensional nature of sarcopenia. Older age, higher BMI, and pain were predictors of transition from the normal state toward sarcopenia. Conversely, moderate physical activity and lower IL-6 were predictive of transitions from presarcopenia to more normal states. These results provide a first step toward characterizing the natural time course of sarcopenia and identifying individuals who may be at risk of developing sarcopenia.
There were several factors associated with transition toward sarcopenia and out of presarcopenia to more normal states. Older participants had increased odds of transition to sarcopenia, which was expected since the prevalence of sarcopenia increases with age (22) . The finding of higher BMI as a predictor of transition to sarcopenia is consistent with previous reports showing a relationship between high BMI and risk of functional impairment (23, 24) . These results also suggest physical activity may be protective of transition toward sarcopenia and transitioning out of presarcopenia to more normal states. Pain was also a significant predictor of transition toward sarcopenia, which may reflect avoidance of physical activity due to pain-related fear (25) . Alternatively, pain may indicate inflammation that contributes to muscle loss (26) although TNF-α and IL-6 were not associated with transitions toward sarcopenia. Sex was not related to transitions possibly due to the sex-specific criteria used for ALM and strength. Race also did not predict transition to sarcopenia despite studies that show that body composition (27, 28) and changes in body composition vary by race (29, 30) . However, it is possible that results would differ with inclusion of additional racial backgrounds.
Little is known regarding the time course of sarcopenia, but a study of bone loss that often accompanies muscle loss (29,31) mirrors our results. Gourlay et al. (32) reported a relationship between transition time to osteoporosis and initial bone mineral density such that less than 10% of women with normal bone density or mild osteopenia transitioned to osteoporosis over 15 years, whereas women with moderate or advanced osteopenia transitioned to osteoporosis in 5 years and 1 year, respectively. Although translation of these results to clinical guidelines was controversial (33, 34) , it supports the notion observed here that few individuals with greater initial reserve transition to worse states.
In contrast to bone mineral density, there are no guidelines for sarcopenia screening. This is due in part to inconsistent diagnostic criteria, need for imaging to quantify ALM, and the absence of effective treatments. Nevertheless, health risks attributable to sarcopenia are far reaching, including morbidity (35), disability (36) , high health care costs (37) , and, as observed here, mortality. Thus, identifying individuals with sarcopenia is important for clinical practice and for advancing treatment development. Our results suggest that if screening guidelines are developed, there is a need for multidimensional assessment of sarcopenia as states with low ALM in combination with low performance and/or strength were more likely to lead to death than low ALM alone. This is supported by studies that report inconsistent relationships between ALM and disability in old age (36, 38, 39) . Additionally, our results suggest the need for early identification as once individuals are sarcopenic, they are unlikely to transition out. Inclusion of subclinical states of sarcopenia characterized here may assist in early identification. Age, self-reported physical activity, BMI, and pain history may also be useful indicators of individuals at risk of transitioning to sarcopenia. Initial is the prevalence of each state at year 1, ie. 54% of participants are initially in state 1. The transition probability indicates the probability of transition from a row state to a column state, ie, participants who are initially in state 1 have 88% probability of staying in state 1 (row 1 column 1), 6% probability of transition to state 2 (row 1, column 2), a 3% probability of transition to state 3 (row 1, column 3), etc. Rows may not sum to 100 due to rounding.
A strength of this study was the use of HMM that is robust to missing data and resulted in the identification of intermediate subclinical states of sarcopenia that are not outlined in current sarcopenia definitions. A further strength was the rich data set of serial grip strength, gait speed, and dual energy x-ray absorptiometry measurements over 9 years and population of individuals without mobility disability at baseline, a mix of sex and two races. Those without mobility disability represent approximately 70% of the population aged 70-79 (NHANES 2009 (NHANES -2010 . However, since our population was restricted to initially well-functioning individuals, states and transition probabilities may differ for less healthy populations or other ages. Our analysis utilized dual energy x-ray absorptiometry measurements of ALM rather than direct assessment of skeletal muscle as computed tomography was performed at only three time points in our population. Data on muscle fat infiltration, which reflects muscle quality, may also provide important information on transitions toward low muscle function beyond the functional measures assessed here. Notes: IU = international units; IL-6 = interleukin 6; TNF-α = tumor necrosis factor-alpha. p-value from chi-square. *Reference category never smoker. †Reference category <500 kcal/wk. ‡Reference category excellent health. §Reference category no pain.
Conclusions
Our results may have important clinical implications for the identification of sarcopenia. First, it suggests that sarcopenia is not simply the presence of low ALM, strength, and performance; there are several intermediate subclinical states that may be important in the progression to sarcopenia. Second, it identifies pain, physical activity, and BMI, three potentially modifiable factors, as determinants of transitions. Finally, since none of the individuals with normal ALM, strength, and performance transitioned to sarcopenia, this may indicate the importance of health promotion earlier in life such that individuals enter old age with a healthy reserve of ALM, muscle strength, and performance.
